861448-78-4

Basic information

• Product Name: [3-(2-amino-2-methylpropyl)phenyl]acetic acid methyl ester
• Synonyms: [3-(2-amino-2-methylpropyl)phenyl]acetic acid methyl ester
• CAS NO: 861448-78-4
• Molecular Weight: 221.299
• Mol File: 861448-78-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: [3-(2-amino-2-methylpropyl)phenyl]acetic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [3-(2-amino-2-methylpropyl)phenyl]acetic acid methyl ester(861448-78-4)
• EPA Substance Registry System: [3-(2-amino-2-methylpropyl)phenyl]acetic acid methyl ester(861448-78-4)

Safety Data

• Hazardous Substances Data: 861448-78-4(Hazardous Substances Data)

Usage

Description

[3-(2-amino-2-methylpropyl)phenyl]acetic acid methyl ester, also known as Meclofenoxate, is a chemical compound that functions as a nootropic or cognitive enhancer. It is structurally related to the neurotransmitter acetylcholine and has been demonstrated to enhance memory, learning, and cognitive function. Meclofenoxate is thought to increase the production of acetylcholine in the brain, which leads to improved communication between neurons and overall cognitive enhancement. Additionally, it has been investigated for its potential neuroprotective and anti-aging effects.

Uses

Used in Pharmaceutical Industry:
Meclofenoxate is used as a cognitive enhancer for promoting memory, learning, and cognitive function. Its ability to increase the production of acetylcholine in the brain leads to improved communication between neurons, resulting in enhanced cognitive abilities.
Used in Dietary Supplements:
Meclofenoxate is also utilized in dietary supplements to support cognitive function and brain health. Its nootropic properties make it a popular choice for individuals seeking to improve their cognitive performance and maintain brain health.
Used in Research and Development:
[3-(2-amino-2-methylpropyl)phenyl]acetic acid methyl ester is used in research and development for its potential neuroprotective and anti-aging effects. Further studies are being conducted to explore its full range of benefits and applications in the field of neuroscience and cognitive health.

Upstream product

• 67-56-1 methanol 
• 1313220-75-5 C₁₂H₁₇NO₂ 
• 808768-95-8 (3-{2-[(chloroacetyl)amino]-2-methylpropyl}phenyl)acetic acid 

Downstream Products

• 865811-33-2 methyl (3-{2-[((2R)-2-[4-(benzyloxy)-3-(hydroxymethyl)phenyl]-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]-2-methylpropyl}phenyl)acetate 
• 865723-31-5 (3-{2-[2-(2,2-dimethyl-4H-[1,3]dioxino[5,4-b]pyridin-6-yl)-2-hydroxyethylamino]-2-methylpropyl}phenyl) acetic acid methyl ester 
• 865799-67-3 (3-{2-[(R)-2-(3,5-bis-benzyloxy-phenyl)-2-(tert-butyl-dimethyl-silanyloxy)-ethylamino]-2-methyl-propyl}-phenyl)-acetic acid methyl ester 
• 866085-69-0 methyl (3-{2-[((2R)-2-[3-[(aminocarbonyl)amino]-4-(benzyloxy)phenyl]-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]-2-methylpropyl}phenyl)acetate 
• 864412-40-8 methyl (3-{2-[((2R)-2-[8-(benzyloxy)-2-oxo-1,2-dihydroquinolin-5-yl]-2-{[tert-butyl(dimethyl)silyl]oxy}ethyl)amino]-2-methylpropyl}phenyl)acetate 
• 865799-38-8 methyl {3-[2-({2-[3,5-bis(benzyloxy)phenyl]-2-hydroxyethyl}amino)-2-methylpropyl]phenyl}acetate 
• 865589-69-1 [3-(2-tert-butoxycarbonylamino-2-methylpropyl)phenyl]acetic acid methyl ester 
• 861448-79-5 (3-{2-[(2R)-2-(4-benzyloxy-3-methanesulfonylaminophenyl)-2-(tert-butyldimethylsilanyloxy)ethylamino]-2-methylpropyl}phenyl)acetic acid methyl ester 

Relevant articles and documents

Inhalation by design: Novel ultra-long-acting β2- adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup

A novel series of potent and selective sulfonamide derived β2-adrenoreceptor agonists are described that exhibit potential as inhaled ultra-long-acting bronchodilators for the treatment of asthma and chronic obstructive pulmonary disease. Analogues from this series mediate very long-lasting smooth muscle relaxation in guinea pig tracheal strips. The sulfonamide agonist headgroup confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state. Optimization of pharmacokinetic properties was achieved through targeted introduction of a phenolic moiety to support rapid phase II clearance, thereby minimizing systemic exposure following inhalation and reducing systemically mediated adverse events. Compound 38 (PF-610355) is identified as a clinical candidate from this series, with in vivo duration of action studies confirming its potential for once-daily use in humans. Compound 38 is currently in advanced phase II clinical studies.

Sulfonamide derivatives for the treatment of diseases

The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

COMPOUNDS FOR THE TREATMENT OF DISEASES

The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in